-
公开(公告)号:US20210363208A1
公开(公告)日:2021-11-25
申请号:US17371755
申请日:2021-07-09
Applicant: Immatics Biotechnologies GmbH
Inventor: Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , C07K14/74 , C07K16/30 , C07K14/725 , C12N5/0783 , C12N15/10 , A61K39/00 , C12N15/115 , G01N33/574 , A61P35/00 , C07K16/28 , A61K35/17 , C07K7/06 , C07K14/54
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20210347822A1
公开(公告)日:2021-11-11
申请号:US17384152
申请日:2021-07-23
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor: Toni WEINSCHENK , Oliver SCHOOR , Claudia TRAUTWEIN , Norbert HILF , Steffen WALTER , Harpreet SINGH
IPC: C07K7/06 , A61K39/00 , C07K7/08 , A61K35/17 , G01N33/574 , C07K14/74 , A61M5/00 , C12N5/0783
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号:US20210346465A1
公开(公告)日:2021-11-11
申请号:US17383855
申请日:2021-07-23
Applicant: Immatics Biotechnologies GmbH
Inventor: Jens FRITSCHE , Toni WEINSCHENK , Steffen WALTER , Peter LEWANDROWSKI , Harpreet SINGH
Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
-
公开(公告)号:US20210292367A1
公开(公告)日:2021-09-23
申请号:US17339157
申请日:2021-06-04
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K7/08 , G01N33/68 , C07K16/18 , C12N15/115 , A61K39/00 , C07K14/47 , C07K14/725 , C07K7/06 , A61K35/17
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
545.
公开(公告)号:US20210277088A1
公开(公告)日:2021-09-09
申请号:US17314688
申请日:2021-05-07
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/74 , A61K39/00 , C07K14/47 , C07K14/635 , C07K14/725 , C07K16/28 , C12N5/0783 , C12Q1/6886 , G01N33/574 , A61K35/17
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20210275655A1
公开(公告)日:2021-09-09
申请号:US17327193
申请日:2021-05-21
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Claudia WAGNER , Julia LEIBOLD , Colette SONG
IPC: A61K39/00 , A61P35/00 , G16B20/20 , A61K35/17 , C07K14/47 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12Q1/6886 , G01N33/574
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20210268063A1
公开(公告)日:2021-09-02
申请号:US17320782
申请日:2021-05-14
Applicant: Immatics Biotechnologies GmbH
Inventor: Jens FRITSCHE , Toni WEINSCHENK , Steffen WALTER , Peter LEWANDROWSKI , Harpreet SINGH
Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
-
公开(公告)号:US20210228697A1
公开(公告)日:2021-07-29
申请号:US17165638
申请日:2021-02-02
Applicant: Immatics Biotechnologies GmbH
Inventor: Sabrina KUTTRUFF-COQUI , Toni WEINSCHENK , Jens FRITSCHE , Steffen WALTER , Norbert HILF , Oliver SCHOOR , Colette SONG , Harpreet SINGH
IPC: A61K39/00 , C07K14/47 , C07K14/705 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/74 , C07K16/28 , C12Q1/6886
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
549.
公开(公告)号:US20210154284A1
公开(公告)日:2021-05-27
申请号:US17165457
申请日:2021-02-02
Applicant: Immatics Biotechnologies GmbH
Inventor: Oliver SCHOOR , Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C07K14/47 , C07K14/705 , C07K14/725 , C07K14/74 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20210138052A1
公开(公告)日:2021-05-13
申请号:US17149241
申请日:2021-01-14
Applicant: Immatics Biotechnologies GmbH
Inventor: Colette SONG , Linus BACKERT , Heiko SCHUSTER , Daniel Johannes KOWALEWSKI , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-